TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Up 18.2% – Still a Buy?

Posted by ABMN Staff on Mar 19th, 2026

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report) rose 18.2% during trading on Wednesday . The stock traded as high as $1.48 and last traded at $1.75. Approximately 2,612 shares traded hands during mid-day trading, a decline of 56% from the average daily volume of 5,928 shares. The stock had previously closed at $1.48.

TriSalus Life Sciences Trading Up 18.2%

The stock has a fifty day simple moving average of $1.41 and a two-hundred day simple moving average of $1.40.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds have recently bought and sold shares of the company. Aristeia Capital L.L.C. bought a new stake in TriSalus Life Sciences during the 4th quarter worth approximately $43,000. Fort Baker Capital Management LP purchased a new stake in TriSalus Life Sciences in the 4th quarter worth approximately $44,000. Cerity Partners LLC bought a new position in TriSalus Life Sciences in the 4th quarter valued at $1,374,000. Finally, Citadel Advisors LLC boosted its holdings in TriSalus Life Sciences by 439.0% in the 3rd quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock valued at $199,000 after purchasing an additional 103,336 shares during the period.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.